tradingkey.logo
tradingkey.logo
Search

Penumbra Inc

PEN
Add to Watchlist
315.520USD
-1.110-0.35%
Close 06/29, 16:00ETQuotes delayed by 15 min
12.41BMarket Cap
72.07P/E TTM

Penumbra Inc

315.520
-1.110-0.35%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

-0.35%

5 Days

-0.22%

1 Month

-0.87%

6 Months

+0.20%

Year to Date

+1.48%

1 Year

+23.04%

Key Figures
317.670Open
317.670High
330.77KVolume
72.07P/E TTM
48.95P/E Dynamic
--Dividend TTM
0.84%Turnover Ratio
316.630Prev. Close
315.460Low
45.09MTurnover
885.51P/E Static
8.42P/B
0.00%Div Yield TTM
9.80%ROA
362.41052wk High
0.84Volume Ratio
14.01MNet Profit
39.32MShares
4.3781EPS TTM
0.71Beta
12.73%ROE
221.26052wk Low
0.70%Amplitude
67.62%Gross Margin
12.41BMarket Cap
-0.38Reward/Risk
1.38%Risk Rate

TradingKey Stock Score of Penumbra Inc

Currency: USD Updated: 2026-06-29

Key Insights

Penumbra Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 67 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 368.88.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Penumbra Inc's Score

Industry at a Glance

Industry Ranking
67 / 204
Overall Ranking
171 / 4570
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Penumbra Inc Highlights

StrengthsRisks
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.61% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.40B.
Undervalued
The company’s latest PE is 72.05, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 37.73M shares, decreasing 6.29% quarter-over-quarter.
Held by George Soros
Star Investor George Soros holds 208.53K shares of this stock.

Analyst Rating

Based on 17 analysts
Hold
Current Rating
368.875
Target Price
+16.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Penumbra Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Penumbra Inc Info

Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Ticker SymbolPEN
CompanyPenumbra Inc
CEOElsesser (Adam)
Websitehttps://www.penumbrainc.com/

FAQs

What is the current price of Penumbra Inc (PEN)?

The current price of Penumbra Inc (PEN) is 315.52.

What is the symbol of Penumbra Inc?

The ticker symbol of Penumbra Inc is PEN.

What is the 52-week high of Penumbra Inc?

The 52-week high of Penumbra Inc is 362.41.

What is the 52-week low of Penumbra Inc?

The 52-week low of Penumbra Inc is 221.26.

What is the market capitalization of Penumbra Inc?

The market capitalization of Penumbra Inc is 12.41B.

Is Penumbra Inc (PEN) currently rated as Buy, Hold, or Sell?

According to analysts, Penumbra Inc (PEN) has an overall rating of signal_hold, with a price target of 368.88.

What is the Earnings Per Share (EPS TTM) of Penumbra Inc (PEN)?

The Earnings Per Share (EPS TTM) of Penumbra Inc (PEN) is 4.57.
KeyAI